Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;19(5):e70105.
doi: 10.1111/irv.70105.

Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants

María Luz García-García  1   2   3 , Patricia Alonso-López  1   2 , Sonia Alcolea  1 , M Arroyas  1   2 , Francisco Pozo  4   5 , Inmaculada Casas  4   5 , Maria Iglesias-Caballero  4 , Rocío Sánchez-León  6 , Jara Hurtado-Gallego  6 , Cristina Calvo  3   6   7
Affiliations

Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants

María Luz García-García et al. Influenza Other Respir Viruses. 2025 May.

Abstract

Background: Nirsevimab, a monoclonal antibody providing passive immunity against RSV infections in infants, was introduced in Spain in October 2023 for children under 6 months and those born during the epidemic season. This study aimed to compare the clinical and virological characteristics of respiratory infections in hospitalized infants before and after nirsevimab introduction.

Methods: We carried out a prospective study across two hospitals in Madrid during the 2022-2023 and 2023-2024 epidemic seasons. The study included infants under 12 months of age that were hospitalized with lower respiratory tract infections (LRTIs). Clinical, epidemiological, and virological data were analyzed and compared between the periods before and after the introduction of nirsevimab, as well as according to whether the infants had received this preventive treatment.

Results: A total of 669 infants were included: 480 from October 2022 to March 2023 (S1) and 189 from October 2023 to March 2024 (S2). Respiratory infection-related admissions decreased by 62.5% in S2, with a 74.5% reduction in ICU admissions. RSV-related admissions decreased by 78%, HMPV by 36.6%, and adenovirus by 69.5%. Infants in S2 were older (p = 0.001) and had shorter hospital stays (p < 0.001) than in S1. Of 63 (33%) infants in S2 who received nirsevimab, 11 (17%) were diagnosed with RSV. High-flow oxygen use was less frequent among RSV patients treated with nirsevimab (p = 0.002).

Conclusions: Nirsevimab introduction was significantly associated with reduced hospitalizations and severity of RSV and other respiratory infections. Its use was associated with fewer admissions and reduced need for intensive care, especially in RSV-infected infants but also in HMPV and adenovirus-infected infants.

Keywords: bronchiolitis; nirsevimab; respiratory infections; respiratory syncytial virus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Number of infants less than 12 months of age admitted for lower respiratory tract infection before (S1) and after the introduction of nirsevimab in Spain (S2).
FIGURE 2
FIGURE 2
(a) Monthly distribution of respiratory admissions between October 1, 2022, and March 31, 2023 (S1/prenirsevimab) and October 1, 2023, and March 31, 2024 (S2/postnirsevimab). (b) Monthly distribution of respiratory admissions between October 1, 2022, and March 31, 2023 (S1/prenirsevimab), and October 1, 2023, and March 31, 2024 (S2/postnirsevimab), in infants who received nirsevimab and those who did not.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Martinon‐Torres F., Carmo M., Platero L., et al., “Clinical and Economic Hospital Burden of Acute Respiratory Infection (BARI) due to Respiratory Syncytial Virus in Spanish Children, 2015–2018,” BMC Infectious Diseases 23 (2023): 385. - PMC - PubMed
    1. Li Y., Wang X., Blau D. M., et al., “Global, Regional and National Disease Burden Estimates of Acute Lower Respiratory Infections due to Respiratory Syncytial Virus in Children Younger Than 5 Years in 2019: A Systematic Analysis,” Lancet 399, no. 10340 (2022): 2047–2064. - PMC - PubMed
    1. Wildenbeest J. G., Billard M.‐N., Zuurbier R. P., et al., “The Burden of Respiratory Syncytial Virus in Healthy Term‐Born Infants in Europe: A Prospective Birth Cohort Study,” Lancet Respiratory Medicine 11 (2023): 341–353. - PMC - PubMed
    1. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection,” Pediatrics 134, no. 2 (2014): 415–420. - PubMed
    1. Jones J. M., Fleming‐Dutra K. E., Prill M. M., et al., “Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices ‐ United States, 2023,” MMWR. Morbidity and Mortality Weekly Report 72 (2023): 920–925. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources